Cancer marker profile (Gall Bladder)50+ booked in last 3 days
Gall bladder cancer occurs due to formation of malignant cells or cancer cells in the gall bladder. The diagnosis or initial screening is done by certain cancer marker tests. Cancer markers or tumour markers are proteins produced by the normal cells as well as cancer cells, but are produced in higher levels by the cancer cells. Cancer marker profile (Gall Bladder)- consists of tests to measure the levels of tumour markers in the blood, urine, and other body fluids. This profile test is used along with other tests may be helpful in the diagnosis of gall bladder and decide the treatment prognosis.
WRITTEN BY: Dr.Shibani R Medical Writer, Medical Affairs
Cancer marker profile (Gall Bladder) Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the Cancer marker profile (Gall Bladder) with a clear pricing structure.
The Cancer marker profile (Gall Bladder) Price in Mumbai is ₹ 1,695 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
The Cancer marker profile (Gall Bladder)- measures the Ca 19.9, CEA levels in the blood.
- The test is useful for the initial screening of cancer: This may include patients with suspected clinical signs and symptoms of gall bladder cancer.
- For monitoring treatment and relapse in patients with pancreatic adenocarcinoma.
- The test may be used as a prognostic marker for survival following pancreatic or gall bladder surgery.
- To know the stage of cancer as well as the metastasis status
- The test can help detect recurrence, metastasis and residual cancer: This may even include patients with a history of cancer of other organs like breast, lung, pancreas etc.
Gall bladder is a rare form of cancer and often goes undetected due to the lack of specific signs and symptoms. Some clinical signs that may require further testing may include:
- Abdominal pain, mainly right upper abdomen.
- Abnormal abdominal bloating
- Jaundice (yellowing of eyes and skin)
- Uncontrolled loss of weight with malaise.
The other group of patients who may also require testing include:
- Patients already undergoing treatment for cancer.
- Patients who have completed the treatment to know the disease status.
- Familial history of cancers.
- Presence of high risk factors for gall bladder cancer like chronic alcoholic, smoker, high diabetic etc.
This test requires a blood sample. A tourniquet (elastic) band is placed tightly on the upper arm. The patient is then asked to make a fist. This helps in the build-up of blood filling the veins. The skin is disinfected before needle insertion and the blood sample is collected in vacutainer.
A gross increase of CEA in a patient with compatible symptoms are suggestive of the presence of cancer. The results of this test when done over an interval help monitor condition of the patient and his response to treatment.
CEA levels fall after successful treatment to normal levels in 1-4 months
Levels may increase in certain non-cancerous conditions like smoking, hepatic disease, trauma, ulcerative colitis, pancreatitis, cirrhosis, COPD, Crohn's disease and hypothyroidism.
Patients should do a follow-up testing preferably through the same laboratory as different assays can give different result values on the same sample
CA 19.9 test
Elevated values occur in cholangiocarcinoma, pancreatic cancer and colon cancer; they may also occur in non-cancerous conditions like cirrhosis, cholestasis and pancreatitis.
In benign conditions the result values are usually below 1000 U/mL.
Patients should do a follow-up testing preferably through the same laboratory as different assays can give different result values on the same sample.
- CEA test
- Ca 19.9 test
- Gall bladder cancer test
Carcinoembryonic antigen (CEA) is a glycoprotein and its concentration in blood increases in certain tumours i.e., colorectal cancer, medullary thyroid carcinoma, breast, gastrointestinal tract, liver, lung, ovarian, pancreatic and prostatic cancers.
It is often used for monitoring colorectal & gastrointestinal cancer patients and their response to treatment.
CA 19-9 is a modified blood group antigen. The levels of CA 19.9 are useful for diagnosis in patients with pancreatic carcinoma, bile duct carcinomas, gastric carcinomas, colon carcinomas, esophageal carcinomas and hepatocellular carcinoma.
Ratings & Reviews (0)
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.